Alnylam Pharmace. buy Piper Sandler
Start price
14.12.23
/
50%
€169.60
Target price
14.12.24
€197.08
Performance (%)
36.79%
End price
15.12.24
€232.00
Summary
This prediction ended on 15.12.24 with a price of €232.00. The BUY prediction by Piper_Sandler for Alnylam Pharmace. saw massive gains of 36.79%. Piper_Sandler has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. Piper_Sandler has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | -1.954% | -1.954% | 49.980% |
| iShares Core DAX® | -1.601% | -2.870% | 23.766% |
| iShares Nasdaq 100 | -3.257% | 2.028% | 12.826% |
| iShares Nikkei 225® | -1.085% | 3.422% | 18.100% |
| iShares S&P 500 | -1.858% | 1.235% | 6.568% |
Comments by Piper_Sandler for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Piper Sandler from $210.00 to $217.00. They now have an "overweight" rating on the stock.
Ratings data for ALNY provided by MarketBeat
In the thread Trading Alnylam Pharmace.
Die von Piper_Sandler gewählte maximale Laufzeit wurde überschritten